{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-25-000051","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.544552+00:00","generated_at":"2026-05-17T14:36:52.773629+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics Q2 net loss $6.0M; Phase 3 T1D trial randomized","bullets":["Net loss attributable to vTv shareholders of $6.0M ($0.92/share) vs $5.2M ($0.81/share) in Q2 2024.","Cash and cash equivalents $25.9M at June 30, 2025, down from $36.7M at December 31, 2024.","First patient randomized in Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes; topline data expected H2 2026.","Appointed Michael Tung, MD, MBA as CFO in May 2025.","USPTO allowed patent claims for crystalline salt form of cadisegliatin with term through 2041."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-25-000051","json":"https://secwatch.observer/filing/0001641489-25-000051.json","markdown":"https://secwatch.observer/filing/0001641489-25-000051.md","text":"https://secwatch.observer/filing/0001641489-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/0001641489-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/vtvt-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:36:52.773629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}